Researchers have identified a key enzyme that cancerous tumours rely on to grow and spread within the body. Described as cancer’s “Achilles Heel”, scientists believe that targeting this enzyme stops tumour cells from growing and spreading. The findings could accelerate the development of new treatments for solid-tumour cancers. Solid cancerous tumours rely on an available […]
ctDNA accurate at diagnosing rectal cancer relapse
Posted: 17th September 2021
Categories: Industry news
Combining circulating tumour DNA (ctDNA) with magnetic resonance imaging (MRI) can more accurately predict the likelihood of locally advanced rectal cancer (LARC) returning after treatment, Chinese scientists have found. In a new study published in PLOS Medicine, researchers describe how combining the techniques improved diagnosis and could improve treatment and outcomes for patients. In addition, […]
Measuring circulating tumour DNA can improve bladder cancer treatment
Posted: 1st September 2021
Categories: Industry news
The presence of circulating tumour DNA (ctDNA) is a crucial biomarker for patients with bladder cancer (urothelial carcinoma) researchers have found in a new study. Scientists suggest that post-operative screening for ctDNA could improve cancer treatments and patient outcomes. The authors hope the findings could help improve outcomes for bladder cancer and more broadly illustrates […]
Promising new immunotherapy for colorectal cancer patients
Posted: 19th August 2021
Categories: Industry news
Patients with advanced colorectal cancer can benefit from treatment with advanced immunotherapy, known as immune checkpoint inhibitor PD-1/PD-L1, scientists have discovered. The findings provide new hope for colorectal cancer patients and more broadly demonstrate the incredible potential for immunotherapies to extend life and treat all forms of cancer. If chemotherapy fails, patients with microsatellite stable […]
New breast cancer therapy a step closer to clinical trials
Posted: 23rd July 2021
Categories: Industry news, RGCC news
An advanced cancer therapy developed by RGCC scientists has been categorised as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA). Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Due to enter clinical trials […]
Activating p53 protein improves cancer-killing potential
Posted: 21st July 2021
Categories: Industry news, RGCC news
Activating protein p53 can boost a patient’s immune response against cancerous tumours, researchers at Sweden’s Karolinska Institutet have discovered. Using a commercially available substance known as ALRN-6924, the team successfully generated an anti-tumour immune response. The finding improves our understanding of the crucial role p53 plays in tumour development. In the future, it could help […]
RGCC scientists develop novel new approach to inhibiting SARS-COV-2 replication
Posted: 23rd June 2021
Categories: Industry news, RGCC news
RGCC researchers have developed a new approach to tackling COVID-19 (SARS-CoV-2) that could form the basis of a new treatment option. Laboratory tests have established that the new treatments were effective at inhibiting the spread of the disease. The next stage will see them progress to develop a drug delivery system, a further step before […]
A new cancer vaccine is 75% effective at eliminating cancerous tumours in mice, say scientists at the University of Konstanz. The combination treatment includes a powerful immunostimulant and a targeted immunotherapy called a cancer checkpoint inhibitor in one dose. Described by the team as a “potent cancer vaccine”, the combination therapy is already being tested […]
New blood test can diagnose cancer without tumour sample
Posted: 24th May 2021
Categories: Industry news
US scientists have developed the world’s first ‘tumour-uninformed’ test that can detect cancer DNA circulating in the blood of cancer patients following treatment. The liquid biopsy test enables clinicians to test for cancer without needing a sample of tumour tissue. It’s an exciting development and adds yet more evidence to the potential for liquid biopsies […]
New Genistein capsule offers improved cancer-killing properties
Posted: 10th May 2021
Categories: Industry news, RGCC news
RGCC scientists have developed a new anti-cancer dietary supplement that’s 34% more effective than the leading brand. Led by RGCC’s Dr Ioannis Papasotiriou, the new product offers yet more evidence of the potential for dietary supplements in the battle against cancer. It also demonstrates RGCC’s cutting-edge research and discovery capabilities. Genistein is a naturally occurring […]
Personalised cancer vaccine 45% effective at targeting tumours
Posted: 29th April 2021
Categories: Industry news, RGCC news
Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour response. The findings provide more […]
US researchers have developed the first systemic way to catch and release cancer-killing packets, called exomes. Thousands of times smaller than natural killer (NK) cells, natural killer exomes can better penetrate cancer cells and destroy them. The authors hope that the ability to capture NK exomes could lead to more advanced and personalised treatments for […]